All In Biotech

Drug Trial Radar · NCT07187960

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Randomized, Open Label, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Relapsed/Refractory Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Nov 2025

Primary completion

Oct 2028

Study completion Feb 2029

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.

Conditions

  • Follicular Lymphoma

Interventions

  • TQB2825 InjectionDrug

    TQB2825 is a Cluster of Differentiation 3 (CD3) × Cluster of Differentiation 20 (CD20) bispecific antibody.

  • Rituximab InjectionDrug

    Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA, Dexamethasone)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) evaluated by an independent review committee (IRC)Time frame: 2 years

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • Sun Yet-Sen University Cancer Certer

    Guangzhou, Guangdong, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital Of Zhengzhou University

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • People's Hospital of Hunan Province

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • The Second Hospital Of Dalian Medical University

    Dalian, Liaoning, China

  • Shengjing Hospital Of China Medical University

    Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Linyi City People Hospital

    Linyi, Shandong, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Tongji Hospital of Tongji University

    Shanghai, Shanghai Municipality, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • People's Hospital of Tianjin

    Tianjin, Tianjin Municipality, China

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, China

  • The First People's Hospital Of Yunnan Province

    Kunming, Yunnan, China

  • Yunan Cancer Hospital

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.